Study summary
A long-acting interferon gave durable blood-count responses in 60% of North American patients
60.2%durable blood-count response
What was tested
Ropeginterferon alfa-2b, a long-acting interferon injection given every 2 to 4 weeks, for essential thrombocythemia, both untreated and after hydroxyurea.
What they found
- Durable response at months 10 and 13 was 60.2%.
- Median time to response was 8.4 weeks.
- Some people had falling driver-mutation levels (35% with JAK2).
What it means
Supports interferon, already approved for polycythemia vera, as a disease-modifying option for ET.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.